FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251138559> ?p ?o ?g. }

• W4251138559 endingPage "185" @default.
• W4251138559 startingPage "181" @default.
• W4251138559 abstract "<b><i>Background:</i></b> Cholangiocarcinomas (CCAs) are aggressive malignancies that display features of biliary differentiation. According to their anatomical location, CCAs are commonly classified as intrahepatic and extrahepatic tumors, the latter entity being further subdivided into perihilar CCAs, also termed as Klatskin tumors, and distal tumors. While a majority of CCAs occur sporadically, established risk factors such as liver fluke infestation or primary sclerosing cholangitis exist. <b><i>Summary:</i></b> Due to lack of efficient early screening markers, CCAs are frequently diagnosed at an advanced stage when curative surgical resection is not an option. Chemotherapy with gemcitabine and cisplatin is currently the standard palliative treatment that prolongs overall survival by 3.6 months as compared to monotherapy with gemcitabine. For CCA patients who progress under gemcitabine/cisplatin, the paucity of prospective, randomized trials is detrimental, and there is currently no recommended second-line regimen with respect to chemotherapy or loco-regional treatment modalities. Molecular profiling of CCAs supports the implementation of targeted approaches, and it is reasonable that personalized therapy will become a mainstay of CCA treatment. In addition, the advent of immunotherapy holds considerable promise, yet, similar to targeted treatment, needs to be prospectively evaluated in clinically and genetically thoroughly characterized patients. <b><i>Key Points:</i></b> (1) CCA is a genetically diverse and highly aggressive malignancy. (2) Gemcitabine in combination with cisplatin or oxaliplatin is the current first-line chemotherapy in non-resectable patients. (3) Loco-regional treatment modalities exist but need to be evaluated in prospective randomized trials in the context of systemic chemotherapy. (4) Targeted therapies in molecularly defined subgroups of patients and immunotherapies alone or in combinations will most likely improve survival in the future." @default.
• W4251138559 created "2022-05-12" @default.
• W4251138559 creator A5022604215 @default.
• W4251138559 creator A5079645039 @default.
• W4251138559 date "2017-01-01" @default.
• W4251138559 modified "2023-10-02" @default.
• W4251138559 title "Cholangiocellular Carcinoma" @default.
• W4251138559 cites W1857369337 @default.
• W4251138559 cites W1903979702 @default.
• W4251138559 cites W1994216489 @default.
• W4251138559 cites W2001620773 @default.
• W4251138559 cites W2006315029 @default.
• W4251138559 cites W2015333951 @default.
• W4251138559 cites W2024003180 @default.
• W4251138559 cites W2032904312 @default.
• W4251138559 cites W2043164178 @default.
• W4251138559 cites W2062374027 @default.
• W4251138559 cites W2063432158 @default.
• W4251138559 cites W2065756402 @default.
• W4251138559 cites W2068110847 @default.
• W4251138559 cites W2078797029 @default.
• W4251138559 cites W2084249495 @default.
• W4251138559 cites W2087336559 @default.
• W4251138559 cites W2087362291 @default.
• W4251138559 cites W2094501197 @default.
• W4251138559 cites W2097924418 @default.
• W4251138559 cites W2105159165 @default.
• W4251138559 cites W2106550415 @default.
• W4251138559 cites W2115261608 @default.
• W4251138559 cites W2123767664 @default.
• W4251138559 cites W2129417801 @default.
• W4251138559 cites W2136629154 @default.
• W4251138559 cites W2139960280 @default.
• W4251138559 cites W2148899606 @default.
• W4251138559 cites W2151650153 @default.
• W4251138559 cites W2151660860 @default.
• W4251138559 cites W2157499993 @default.
• W4251138559 cites W2158725835 @default.
• W4251138559 cites W2160555700 @default.
• W4251138559 cites W2168106806 @default.
• W4251138559 cites W2292046787 @default.
• W4251138559 cites W2309818502 @default.
• W4251138559 cites W2337699335 @default.
• W4251138559 cites W2478338554 @default.
• W4251138559 cites W2508622625 @default.
• W4251138559 doi "https://doi.org/10.1159/000454763" @default.
• W4251138559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28288474" @default.
• W4251138559 hasPublicationYear "2017" @default.
• W4251138559 type Work @default.
• W4251138559 citedByCount "15" @default.
• W4251138559 countsByYear W42511385592017 @default.
• W4251138559 countsByYear W42511385592019 @default.
• W4251138559 countsByYear W42511385592020 @default.
• W4251138559 countsByYear W42511385592021 @default.
• W4251138559 countsByYear W42511385592022 @default.
• W4251138559 countsByYear W42511385592023 @default.
• W4251138559 crossrefType "journal-article" @default.
• W4251138559 hasAuthorship W4251138559A5022604215 @default.
• W4251138559 hasAuthorship W4251138559A5079645039 @default.
• W4251138559 hasBestOaLocation W42511385591 @default.
• W4251138559 hasConcept C121608353 @default.
• W4251138559 hasConcept C126322002 @default.
• W4251138559 hasConcept C143998085 @default.
• W4251138559 hasConcept C2776694085 @default.
• W4251138559 hasConcept C2778239845 @default.
• W4251138559 hasConcept C2779399171 @default.
• W4251138559 hasConcept C2780258809 @default.
• W4251138559 hasConcept C2780962732 @default.
• W4251138559 hasConcept C2781413609 @default.
• W4251138559 hasConcept C526805850 @default.
• W4251138559 hasConcept C71924100 @default.
• W4251138559 hasConcept C90924648 @default.
• W4251138559 hasConceptScore W4251138559C121608353 @default.
• W4251138559 hasConceptScore W4251138559C126322002 @default.
• W4251138559 hasConceptScore W4251138559C143998085 @default.
• W4251138559 hasConceptScore W4251138559C2776694085 @default.
• W4251138559 hasConceptScore W4251138559C2778239845 @default.
• W4251138559 hasConceptScore W4251138559C2779399171 @default.
• W4251138559 hasConceptScore W4251138559C2780258809 @default.
• W4251138559 hasConceptScore W4251138559C2780962732 @default.
• W4251138559 hasConceptScore W4251138559C2781413609 @default.
• W4251138559 hasConceptScore W4251138559C526805850 @default.
• W4251138559 hasConceptScore W4251138559C71924100 @default.
• W4251138559 hasConceptScore W4251138559C90924648 @default.
• W4251138559 hasIssue "3" @default.
• W4251138559 hasLocation W42511385591 @default.
• W4251138559 hasLocation W42511385592 @default.
• W4251138559 hasOpenAccess W4251138559 @default.
• W4251138559 hasPrimaryLocation W42511385591 @default.
• W4251138559 hasRelatedWork W1996550290 @default.
• W4251138559 hasRelatedWork W2028640470 @default.
• W4251138559 hasRelatedWork W2100029565 @default.
• W4251138559 hasRelatedWork W2120848645 @default.
• W4251138559 hasRelatedWork W2364146720 @default.
• W4251138559 hasRelatedWork W2374795505 @default.
• W4251138559 hasRelatedWork W2465617904 @default.
• W4251138559 hasRelatedWork W2590585323 @default.
• W4251138559 hasRelatedWork W4237706359 @default.

• next